FDA Approves Use Of Zika Virus Blood Screener From Hologic And Grifols

Hologic Inc (NASDAQ: HOLX) and Grifols, S.A. (NASDAQ: GRFS) announced Monday that they won FDA approval for the use of the Procleix Zika virus blood screening assay.

U.S. blood centers will use Procleix to screen blood donations in the Southern US and other areas potentially affected by the virus. The American Red Cross has partnered with Hologic and Grifols to perform the Procleix Zika Virus assay investigational study.

Hologic and Grifols shares closed Monday at $34.14 and $15.58, respectively, both up about 1 percent from Friday's close.